What does Dr. B. Vandendriessche Endocrino do?

Dr. B. Vandendriessche Endocrino is a specialist medical practice in Merelbeke-Melle. Private Limited, started on 11 January 2022, 1 establishment.

What is the address of Dr. B. Vandendriessche Endocrino?

The registered office of Dr. B. Vandendriessche Endocrino is located at Gaversesteenweg 392, 9820 Merelbeke-Melle.

Is Dr. B. Vandendriessche Endocrino still active?

Yes. According to the CBE (18 September 2026) Dr. B. Vandendriessche Endocrino is active, legal situation “Normale toestand”, started on 11 January 2022.

Is Dr. B. Vandendriessche Endocrino registered on Peppol?

Yes, Dr. B. Vandendriessche Endocrino is registered on the Peppol network with ID 0208:0779975515.

What is the enterprise number of Dr. B. Vandendriessche Endocrino?

The enterprise number of Dr. B. Vandendriessche Endocrino is BE0779975515.

When was Dr. B. Vandendriessche Endocrino founded?

Dr. B. Vandendriessche Endocrino was founded on 11 January 2022.

Who are the directors of Dr. B. Vandendriessche Endocrino?

According to the 2025 annual accounts, the directors of Dr. B. Vandendriessche Endocrino are: Barbara Vandendriessche.

Is Dr. B. Vandendriessche Endocrino a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 11 January 2022; 4 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did Dr. B. Vandendriessche Endocrino make in 2025?

Dr. B. Vandendriessche Endocrino posted a profit after taxes of € 86,630 in financial year 2025.

What is the revenue of Dr. B. Vandendriessche Endocrino?

As a small company, Dr. B. Vandendriessche Endocrino is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 124,842.

Dr. B. Vandendriessche Endocrino (Private Limited)

Dossier Dr. B. Vandendriessche Endocrino, printed on 18 September 2026 from databakkes.be/en/0779975515/dr-b-vandendriessche-endocrino. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

Dr. B. Vandendriessche Endocrino from Merelbeke-Melle, company number BE0779975515, closed financial year 2025 with a result of € 86,630 after tax. For that financial year Dr. B. Vandendriessche Endocrino recorded a gross margin of € 124,842 and equity of € 210,360. Compared with financial year 2024, the result moved from € 74,497 to € 86,630. Profitable, and profit is growing. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on April 29, 2026.

What it is worth Healthy

€ 210,360

▼ 7% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 86,630

▲ 16% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 109,097

▼ 30% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 101,720 paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2025

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Vehicles and equipment

€ 7,186

▼ 8% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 5,960

▲ 48% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 8,819

▼ 53% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 120,381 Gross margin 2022: € 120,381 First fiscal year in the series	€ 73,225 Gross margin 2023: € 73,225 ▼ 39% vs 2022 (€ 120,381) Unfavourable step	€ 97,057 Gross margin 2024: € 97,057 ▲ 33% vs 2023 (€ 73,225) Favourable step	€ 124,842 Gross margin 2025: € 124,842 ▲ 29% vs 2024 (€ 97,057) Favourable step	▲ 29%
Profit after taxes	€ 93,860 Profit after taxes 2022: € 93,860 First fiscal year in the series	€ 56,253 Profit after taxes 2023: € 56,253 ▼ 40% vs 2022 (€ 93,860) Unfavourable step	€ 74,497 Profit after taxes 2024: € 74,497 ▲ 32% vs 2023 (€ 56,253) Favourable step	€ 86,630 Profit after taxes 2025: € 86,630 ▲ 16% vs 2024 (€ 74,497) Favourable step	▲ 16%
Equity	€ 96,360 Equity 2022: € 96,360 First fiscal year in the series	€ 150,953 Equity 2023: € 150,953 ▲ 57% vs 2022 (€ 96,360) Favourable step	€ 225,450 Equity 2024: € 225,450 ▲ 49% vs 2023 (€ 150,953) Favourable step	€ 210,360 Equity 2025: € 210,360 ▼ 7% vs 2024 (€ 225,450) Unfavourable step	▼ 7%
Total debts	€ 38,057 Total debts 2022: € 38,057 First fiscal year in the series	€ 17,905 Total debts 2023: € 17,905 ▼ 53% vs 2022 (€ 38,057) Favourable step	€ 26,718 Total debts 2024: € 26,718 ▲ 49% vs 2023 (€ 17,905) Unfavourable step	€ 18,924 Total debts 2025: € 18,924 ▼ 29% vs 2024 (€ 26,718) Favourable step	▼ 29%
Cash	€ 42,456 Cash 2022: € 42,456 First fiscal year in the series	€ 79,535 Cash 2023: € 79,535 ▲ 87% vs 2022 (€ 42,456) Favourable step	€ 155,990 Cash 2024: € 155,990 ▲ 96% vs 2023 (€ 79,535) Favourable step	€ 109,097 Cash 2025: € 109,097 ▼ 30% vs 2024 (€ 155,990) Unfavourable step	▼ 30%
Retained profit	€ 93,860 Retained profit 2022: € 93,860 First fiscal year in the series	€ 148,453 Retained profit 2023: € 148,453 ▲ 58% vs 2022 (€ 93,860) Favourable step	€ 222,950 Retained profit 2024: € 222,950 ▲ 50% vs 2023 (€ 148,453) Favourable step	€ 207,860 Retained profit 2025: € 207,860 ▼ 7% vs 2024 (€ 222,950) Unfavourable step	▼ 7%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 1,660 Dividend 2023: € 1,660 Unchanged (€ 0) Unchanged	€ 0 Dividend 2024: € 0 ▼ 100% vs 2023 (€ 1,660) Unchanged	€ 101,720 Dividend 2025: € 101,720 Unchanged (€ 0) Unchanged
Balance sheet total	€ 134,417 Balance sheet total 2022: € 134,417 First fiscal year in the series	€ 168,858 Balance sheet total 2023: € 168,858 ▲ 26% vs 2022 (€ 134,417) Unchanged	€ 252,168 Balance sheet total 2024: € 252,168 ▲ 49% vs 2023 (€ 168,858) Unchanged	€ 229,284 Balance sheet total 2025: € 229,284 ▼ 9% vs 2024 (€ 252,168) Unchanged	▼ 9%

Key figures of Dr. B. Vandendriessche Endocrino, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 April 2027.

What happened to Dr. B. Vandendriessche Endocrino?

What happened at Dr. B. Vandendriessche Endocrino in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Apr 29, 2026 New annual accounts for financial year 2025: profit of € 86,630 (▲ 16% vs 2024). Source: NBB ↗
Jan 11, 2022 New establishment in Gent. KBO
2022 Barbara Vandendriessche became a director. NBB
Jan 11, 2022 Start of the company according to the CBE. KBO

In short

From € 93,860 profit in 2022 to € 86,630 profit in 2025.

Paid € 92,008 in corporate taxes since 2022.

Best year ever: 2022, with € 93,860 profit.

Paid out € 103,380 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at Dr. B. Vandendriessche Endocrino? We notify you, reason included.

Follow Dr. B. Vandendriessche Endocrino

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit